Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | ALPL | P05186 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14910131 | 0.87 | NPC1 (0.51) | MAPTRAB9ANPC1MAPK1ADORA3 | |
| SCHEMBL6226718 | 0.84 | ALDH1A1 (0.53) | MAPTRAB9ANPC1MAPK1ADORA3 | |
| SCHEMBL1855459 | 0.81 | MAPT (0.59) | MAPTRAB9ANPC1MAPK1SMN1; SMN2 | |
| SCHEMBL4858146 | 0.81 | ALDH1A1 (0.62) | MAPTRAB9ANPC1MAPK1ALPL | |
| SCHEMBL1858037 | 0.81 | BTK (0.47) | MAPTRAB9ANPC1MAPK1ADORA3 | |
| SCHEMBL1608422 | 0.80 | RAB9A (0.84) | MAPTRAB9ANPC1MAPK1ADORA3 | |
| SCHEMBL13425914 | 0.80 | RAB9A (0.69) | MAPTRAB9ANPC1MAPK1ADORA3 | |
| SCHEMBL1181434 | 0.80 | RAB9A (1.00) | MAPTRAB9ANPC1MAPK1ADORA3 | |
| SCHEMBL1143959 | 0.79 | ALPL (0.54) | MAPTRAB9ANPC1ALPLLMNA | |
| SCHEMBL20575703 | 0.79 | PDE4A (0.60) | MAPTRAB9ANPC1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118151489-B | Photosensitive resin composition, photosensitive dry film and application thereof | 湖南初源新材料股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118151489-A | Photosensitive resin composition, photosensitive dry film and application thereof | 湖南初源新材料股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-3536692-B1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3536692-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170369499-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9796725-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217968-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3030560-B1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-06-21 | — | — | EP | disclosed |
| WO-2005068473-A1 | BICYCLIC PYRAZOLO-FUSED COMPOUNDS AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-1513522-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | SRI INTERNATIONAL (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2003062392-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | CERETEK LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6559173-B1 | organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | ALLERGAN, INC. | 2003-05-06 | — | — | US | disclosed |
| WO-2003026650-A1 | 3-(HETEROARYLAMINO)METHYLENE-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2002062795-A9 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202389-B2 | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | UBA1, UBXN1, UBE2E1 | MAPT 1899/4885RAB9A 1330/4885NPC1 4338/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | MAPT 96/4885RAB9A 3468/4885NPC1 2341/4885 |
| US-20170369499-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | USP1, UBA1, UBXN1 | MAPT 1946/4885RAB9A 1322/4885NPC1 4212/4885 |
| US-20030130328-A1 | 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | MAPT 3314/4885RAB9A 2354/4885NPC1 3810/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MAPT 519/4885RAB9A 1231/4885NPC1 2700/4885 |
| US-20170217968-A1 | PYRAZOLOPYRIMIDINYL INHIBITORS OF UBIQUITIN-ACTIVATING ENZYME | UBA1, UBXN1, UBE2E1 | MAPT 1899/4885RAB9A 1330/4885NPC1 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.